MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 82,594 Shares of Pfizer Inc. (NYSE:PFE)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 8.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,090,774 shares of the biopharmaceutical company's stock after buying an additional 82,594 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Pfizer were worth $28,934,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Fiduciary Alliance LLC lifted its stake in Pfizer by 15.5% during the fourth quarter. Fiduciary Alliance LLC now owns 9,803 shares of the biopharmaceutical company's stock worth $260,000 after purchasing an additional 1,319 shares during the period. Rosenberg Matthew Hamilton lifted its stake in Pfizer by 59.9% during the fourth quarter. Rosenberg Matthew Hamilton now owns 2,029 shares of the biopharmaceutical company's stock worth $54,000 after purchasing an additional 760 shares during the period. Mayfair Advisory Group LLC lifted its stake in Pfizer by 4.7% during the fourth quarter. Mayfair Advisory Group LLC now owns 10,758 shares of the biopharmaceutical company's stock worth $285,000 after purchasing an additional 479 shares during the period. 626 Financial LLC lifted its stake in Pfizer by 15.4% during the fourth quarter. 626 Financial LLC now owns 48,849 shares of the biopharmaceutical company's stock worth $1,296,000 after purchasing an additional 6,514 shares during the period. Finally, Accurate Wealth Management LLC lifted its stake in Pfizer by 17.6% during the fourth quarter. Accurate Wealth Management LLC now owns 35,736 shares of the biopharmaceutical company's stock worth $955,000 after purchasing an additional 5,360 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of Pfizer stock opened at $22.01 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market cap of $125.13 billion, a P/E ratio of 15.61, a P/E/G ratio of 0.64 and a beta of 0.58. The firm has a 50 day simple moving average of $23.80 and a 200 day simple moving average of $25.44. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the business posted $0.82 earnings per share. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.81%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is presently 124.64%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PFE. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.